Abexxa Biologics,

Abexxa Biologics is a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology to develop the next generation of precision medicine. Abexxa is focused on developing novel therapeutics around its newly discovered class of intracellular antigens (atypical HLA-peptide complexes) on cancerous cells. These atypical HLA-peptide complexes provide access to previously un-druggable targets and have been shown to play a regulatory role in modulating innate and adaptive immune responses. Abexxa has developed a target discovery and validation platform, and a robust method to create highly specific human antibodies to those targets. These are being developed for various therapeutic drug formats, including direct tumor killing as well as mediating tumor death through immune modulation.